le LUMACAFTOR et l'IVACAFTOR, 2 médicaments développés à l'origine pour la mucoviscidose et ayant un effet agoniste du canal hERG, pourraient devenir les nouveaux traitements du syndrome du QT long de type 2 (où ce canal est défaillant) c'est fou non ? htt
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. https://t.co/17Dn2l0abH https://t.co/FC6Zp5edmE
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
Here the latest publication from our group 😊
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
Exciting preliminary results! #lumafactor to rescue trafficking-deficient cardiac #ionchannels in 2 patients - But authors are cautious "The findings are encouraging but immediate translation into clinical practice, without validation in more patients, wou
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
RT @AndreasGevaert: Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clini…
Very promising study @SilCastelletti - great showcase for translational research in #cardiogenetics, from IPSC to clinical application! Eagerly awaiting more clinical data! #cardiotwitter
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored therapy in #LongQTSyndrome #LQTS #genetics @escardio @TomLuscher @rladeiraslopes @BehrElijah @ArthurWilde5 @CSHeartResearch @StefanoNistri